Filing Flows › Caribou Biosciences (CRBU) › Q3 2026 › vs Q3 2025
Caribou Biosciences (CRBU) Q3 2026 vs Q3 2025 (year over year)
Caribou Biosciences's revenue fell $591K (-27%) from $2.2M in Q3 2025 to $1.6M in Q3 2026.
Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year), net loss $26.6M, operating cash flow −$22.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6M | $2.2M | −$591K | -27% |
| Other income, net | $1.0M | $1.9M | −$822K | -44% |
| Net loss | $26.6M | $27.5M | −$936K | -3% |
| Costs & expenses | $29.2M | $31.6M | −$2.3M | -7% |
| Operating costs | $29.2M | $31.6M | −$2.3M | -7% |
| Research & development | $21.3M | $22.4M | −$1.1M | -5% |
| General & admin | $7.9M | $9.2M | −$1.3M | -14% |
| Operating cash sources | $26.6M | $27.5M | −$936K | -3% |
| Depreciation & amortization | $590K | $631K | −$41K | -6% |
| Share-based compensation | $2.2M | $2.9M | −$768K | -26% |
| Working capital & other | $1.3M | −$1.2M | $2.5M | — |
| Cash used in operations | $22.5M | $25.2M | −$2.7M | -11% |
| Net loss absorbed | $26.6M | $27.5M | −$936K | -3% |
Questions
How much did Caribou Biosciences's revenue grow year over year in Q3 2026?
Caribou Biosciences's revenue fell $591K (-27%) from $2.2M in Q3 2025 to $1.6M in Q3 2026.